head-icon1.svgMeet us at an upcoming event
head-icon2.svgIn Stock. Ready to Ship
languageEN
languageEN
icon-arrow-g
counsellingContact Us
languageEN
languageEN
icon-arrow-g

未标题-1.jpg未标题-1.jpg

Insights

Explore our collection of scientific blogs, educational webinars, and research posters. Stay updated with the latest insights in preclinical research and animal model applications.
Subscribe for Updatesarrow-right-warrow-right-g

Featured Blogs

Latest scientific articles and research insights

Learn Morearrow-right-warrow-right-g

Featured Webinars

Educational presentations and expert discussions

Webinar 490X326 (1).pngmask

Upcoming

Oncology

Selecting the Right Humanized Mouse Model for Immuno-Oncology Programs: A Practical Guide to Improving Translational Success

Selecting the right humanized mouse model is one of the most consequential decisions in immuno-oncology (IO) drug development. The wrong model can mask safety liabilities, inflate efficacy estimates, and weaken the data supporting regulatory submissions. Join GemPharmatech for a data-driven webinar on how strategic humanized mouse model selection strengthens preclinical decision-making, sharpens translational relevance, and supports IND-enabling studies.

meetingDate2026-07-30

meetingDuration11:00 AM ET

moderatorXinjie Lian

Register Now arrow-right-warrow-right-g
Webinar 454X302 .pngmask

On-Demand

Cardiovascular Disease

Applications of Genetically Engineered Mouse Models for Hypertrophic Cardiomyopathy Research

Hypertrophic cardiomyopathy (HCM) is a prevalent and genetically heterogeneous cardiovascular disorder, with approximately 55% of familial cases linked to mutations in sarcomeric genes. To enable mechanistic and therapeutic studies, GemPharmatech has successfully developed two HCM mouse models: the Mybpc3 knockout (KO) and the Myh6 R404Q (point mutation) strains.

meetingDate2026-06-25

meetingDuration11:00 AM ET

moderatorYue Shen, Ph.D.

Watch Now arrow-right-warrow-right-g
undefined.pngmask

On-Demand

Oncology

Overcoming ADC Resistance: Construction and Preclinical Applications of Enhertu-Resistant Models

Antibody-drug conjugates (ADCs), particularly the HER2-targeting Enhertu (DS-8201), have revolutionized targeted cancer therapy. Despite their clinical success, drug resistance remains a major hurdle limiting long-term therapeutic benefits. To address this challenge, GemPharmatech has developed multiple ADC resistance models, including a HER2-positive JIMT-1 breast cancer xenograft (CDX) model with acquired resistance to Enhertu, and a primary Enhertu-resistant HER2-positive lung cancer model from our patient-derived xenograft (PDX) library. Join us to explore how these Enhertu-resistant models serve as translational tools to elucidate resistance mechanisms and evaluate novel therapeutic strategies.

meetingDate2026-04-14

meetingDuration11:00 AM ET

moderatorShiying Guo, Ph.D.

Watch Now arrow-right-warrow-right-g
Learn Morearrow-right-warrow-right-g

Featured Posters

Scientific posters from major conferences

Learn Morearrow-right-warrow-right-g

Featured News

Latest company updates and announcements

Learn Morearrow-right-warrow-right-g

Featured Events

Upcoming conferences and trade shows

undefined.png

IMMUNOLOGY2026

meetingDate2026-05-08

Request a 1:1 meeting arrow-right-warrow-right-g
undefined.png

AACR 2026

meetingDate2026-04-17

Book your 1-on-1 arrow-right-warrow-right-g
undefined721_480.png

AD/PD™ 2026

meetingDate2026-03-17

Book your 1-on-87 arrow-right-warrow-right-g
arrow-right-garrow-right-w
arrow-right-garrow-right-w
Learn Morearrow-right-warrow-right-g

zimg7.png

Stay Updated with Latest Research

Subscribe to our newsletter to receive the latest blogs, webinar invitations, and research updates directly to your inbox.

Submit Inquiry

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Area of interest*

Select Area of Interest

Research Focus

Additional Info

Submitarrowarrow

Contact Us

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Area of interest*

Select Area of Interest

Research Focus

How did you hear about us*

Select a source

Leave us a message

Submitarrowarrow

Schedule a Meeting

Let us know which event you're attending and we'd be happy to connect with you.

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Area of interest*

Select Area of Interest

Research Focus

How did you hear about us*

Select a source

Leave us a message

Submitarrowarrow

Download

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Research Focus

Submitarrowarrow

Download

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Research Focus

Submitarrowarrow

Watch On-Demand Webinar

First Name*

Last Name*

Organization*

Email*

Country/Region

Select Country/Region

State/Province*

City

Research Focus

Submitarrowarrow

Newsletter Signup

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

Area of interest*

Select Area of Interest

Research Focus

Submitarrowarrow